A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy ...

This guidance updates and replaces NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088). Next review: This guidance will be ...

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer TA1138 2 March 2026 2 March 2026 ...

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...

This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...

This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission.

This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing ...